Scientific Programme
Programme-at-a-Glance Pre- and Post-Congress Workshops
|
“
|
|
Having a multidisciplinary congress like this is very useful. The tracks for the Academic Clinical Programmes sets a standard and creates a platform for interprofessional as well as inter-institutional staff to come together to share on research, education and clinical service advancement.
|
|
|
|
|
|
|
|
|
”
|
|
|
|
~ Prof Celia Tan Group Director, Allied Health, SingHealth
|
|
|
Programme >
Bleeding Disorders Symposium Targeted Clinical Haemostasis
|
Track type:
Symposium
|
|
Date: 21 Sep 2018
|
|
Time:
1330 - 1500
|
|
Location:
Academia, Level 2, PSL2
|
Haemostasis is the human body's response to blood vessel injury and bleeding. It involves a coordinated interaction between platelets and numerous blood clotting factors, resulting in the formation of a blood clot and subsequent stopping of the bleed. It maintains blood in its fluid state while stopping bleeding in cases of trauma or disease.
Coagulation disorders may involve single clotting factor as in haemophilia, combination of a few specific clotting factors as in anticoagulation drugs or multiple clotting factors as in liver disease or severe trauma. There is a need for more specific treatment beyond giving fresh frozen plasma for any coagulopathy. There is also increasing awareness of the existence of rather broad inter-individual variability in the haemostatic system as well as the dynamic time-dependent changes in coagulation defects. This suggests that individualised and more targeted monitoring and treatments are required. Such management may result in fewer transfusions, improved patient outcomes and reduced hospital costs.
This symposium with the theme of “Targeted Clinical Haemostasis” consists of four speakers with 4 relevant topics: a) Individualised and targeted therapy for Haemophilia, b) Targeted reversal of anticoagulation in patient with bleeding, c) Targeted management of coagulopathy in liver transplant and d) Early and targeted management of trauma-induced coagulopathy.
TOPIC 1:
Individualised and Targeted Therapy for Persons with Haemophilia
TOPIC 2:
Targeted Reversal of Anticoagulation in Patients with Bleeding
TOPIC 3:
Targeted Management of Coagulopathy in Liver Transplant
TOPIC 4:
Early and Targeted Management of Trauma-induced Coagulopathy
*Information is correct at time of update
|
|
|
|
|
|